TP53 mutations and Arg72Pro polymorphism in breast cancers

Cancer Genetics and Cytogenetics

Volumn 192, Issue 2, 2009, Pages 93-95

  Denisov, Evgeniy V ^a,b   Cherdyntseva, Nadejda V ^a   Litvyakov, Nicolay V ^a   Slonimskaya, Elena M ^a   Malinovskaya, Elena A ^a   Voevoda, Mikhail I ^c   Belyavskaya, Valentina A ^d   Stegniy, Vladimir N ^b  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

^b TOMSK STATE UNIVERSITY   (Russian Federation)

^c INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^d STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DNA; PROLINE; PROTEIN P53;

ADULT; AGED; AMINO ACID SUBSTITUTION; BREAST CANCER; CANCER STAGING; CODON; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; DNA POLYMORPHISM; EXON; GENE FREQUENCY; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INTRON; LETTER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION; VARIABLE NUMBER OF TANDEM REPEAT;

AMINO ACID SUBSTITUTION; ARGININE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CODON; GENOTYPE; HUMANS; LYMPHATIC METASTASIS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67649815036     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.03.014     Document Type: Letter

References (13)

1. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 (1999) 1092-1100
2. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
3. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 (2004) 196-199
4. Siddique M., and Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25 (2006) 3489-3500
5. Langerød A., Bukholm I.R., Bregård A., Lønning P.E., Andersen T.I., Rognum T.O., Meling G.I., Lothe R.A., and Børresen-Dale A.L. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11 (2002) 1684-1688
6. Bonafé M., Ceccarelli C., Farabegoli F., Santini D., Taffurelli M., Barbi C., Marzi E., Trapassi C., Storci G., Olivieri F., and Franceschi C. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9 (2003) 4860-4864
7. Siddique M.M., Balram C., Fiszer-Maliszewska L., Aggarwal A., Tan A., Tan P., Soo K.C., and Sabapathy K. Evidence for selective expression of the p53 codon 72 polymorphs: Implications in cancer development. Cancer Epidemiol Biomarkers Prev 14 (2005) 2245-2252
8. Kyndi M., Alsner J., and Hansen L.L. Sørensen FB, Overgaard J. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol 45 (2006) 602-609
9. Ara S., Lee P.S., Hansen M.F., and Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18 (1990) 4961
10. Belyavskaya V.A., Vardosanidze V.K., Smirnova O.Y., Karakin E.I., Savkin I.V., Gervas P.A., Cherdyntseva N.V., and Voevoda M.I. Genetic status of p53 in stomach cancer: somatic mutations and polymorphism of codon 72. Bull Exp Biol Med 141 (2006) 243-246
11. Hahn M., Serth J., Fislage R., Wolfes H., Allhoff E., Jonas V., and Pingoud A. Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin Chem 39 (1993) 549-550
12. Tada M., Furuuchi K., Kaneda M., Matsumoto J., Takahashi M., Hirai A., Mitsumoto Y., Iggo R.D., and Moriuchi T. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 22 (2001) 515-517
13. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., and Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100 (2003) 8424-8429